Neutrophils as a Novel Target of Modified Low-Density Lipoproteins and an Accelerator of Cardiovascular Diseases

Takashi Obama * and Hiroyuki Itabe

Division of Biological Chemistry, Department of Pharmaceutical Sciences, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; h-itabe@pharm.showa-u.ac.jp

Received: 30 September 2020; Accepted: 3 November 2020; Published: 5 November 2020

Abstract: Neutrophil extracellular traps (NETs) significantly contribute to various pathophysiological conditions, including cardiovascular diseases. NET formation in the vasculature exhibits inflammatory and thrombogenic activities on the endothelium. NETs are induced by various stimulants such as exogenous damage-associated molecular patterns (DAMPs). Oxidatively modified low-density lipoprotein (oxLDL) has been physiologically defined as a subpopulation of LDL that comprises various oxidative modifications in the protein components and oxidized lipids, which could act as DAMPs. oxLDL has been recognized as a crucial initiator and accelerator of atherosclerosis through foam cell formation by macrophages; however, recent studies have demonstrated that oxLDL stimulates neutrophils to induce NET formation and enhance NET-mediated inflammatory responses in vascular endothelial cells, thereby suggesting that oxLDL may be involved in cardiovascular diseases through neutrophil activation. As NETs comprise myeloperoxidase and proteases, they have the potential to mediate oxidative modification of lipoproteins. This review summarizes recent updates on the analysis of NETs, their implications for cardiovascular diseases, and prospects for a possible link between NET formation and oxidative modification of lipoproteins.

Keywords: neutrophil extracellular traps; oxidized low-density lipoprotein; endothelial cells; HL-60 cells; inflammatory response

1. Introduction

Although neutrophil extracellular traps (NETs) were initially considered to be one of the first line responses of the immune system against infected bacteria [1], extensive studies have revealed that NET formation is associated with the initiation and progression of various noninfectious diseases [2,3]. In cardiovascular diseases (CVDs), NETs have been found in vascular lesions such as atherosclerotic plaques and thrombi [4]. Numerous studies have demonstrated that the products released from neutrophils during NET formation directly injure vascular tissues and induce inflammation, indicating that NETs contribute to the progression of vascular diseases.

Increased low-density lipoprotein (LDL) levels in plasma are known to be independent risk factors for atherosclerosis. The molecular structure and characteristics of LDL change dramatically in oxidatively modified LDL (oxLDL). Accumulating studies have revealed that oxLDL is present in both atherosclerotic lesions and circulation [5] and plays a pivotal role in the progression of CVDs by promoting foam cell formation as well as initiating endothelial inflammatory responses [6].

LDL is modified by both enzymatic and non-enzymatic actions. For example, myeloperoxidase (MPO) produces reactive oxygen species (ROS) that cause oxidative modifications of proteins and lipids in lipoprotein particles. Neutrophil elastase (NE) has been reported to degrade protein components in LDL [7].
leading to enhanced uptake of modified LDL by macrophages [8]. Neutrophils, in addition to macrophages, are frequently found in vascular lesions; thus, NET formation and the subsequent release of enzymes could presumably potentiate oxLDL production. Furthermore, whether LDL and oxLDL can affect NET formation during CVD development remains unclear. For several years, the biological and pathological effects of neutrophils and lipoproteins on CVDs have been addressed and discussed individually. Insight into the interrelationship between neutrophils and lipoproteins that coexist in the circulation and in vascular lesions under pathological conditions may shed light on a new possibility to understand their roles in vascular diseases.

In this review, we summarize recent updates on the analysis of NETs and their implications for CVDs. A possible link between NET formation and oxidative modification of lipoproteins has also been discussed.

2. Induction of NETs

Neutrophils or polymorphonuclear leukocytes (PMNs) have a short lifespan and are highly susceptible to activation. The human promyelocytic leukemia cell line, HL-60, is widely used in the in vitro analysis of NETs. HL-60 cells can be differentiated into neutrophil-like cells using various pharmacological stimulants, such as all-trans retinoic acid, dimethyl sulfoxide, and dimethylformamide. HL-60-derived neutrophil-like cells reveal NET formation characterized by CD11b expression, DNA release, oxidative burst, and histone citrullination; however, these responses are more pronounced in PMNs than in HL-60 [9]. Phorbol myristate acetate (PMA), a potent protein kinase C activator, is a well-defined NET-inducer [10]. In addition to PMA, several cytokines and chemokines have been reported to induce NET formation, including TNFα, IL-8 [1], IL-18 [11], CXCL7 [12], complement (C5a) [13], and interferons [14]. Moreover, NET formation is primed by crystals of monosodium urate [15,16] and cholesterol [17]. High concentrations of glucose induce NETosis [18], indicating that NET formation is increased in patients with type 2 diabetes [19] and diabetic retinopathy [20]. Furthermore, nicotine also induces NET formation [21], and PMNs from smokers are more susceptible to PMA-induced NET formation than those from nonsmokers [22].

NET release can be classified into two types: (1) “suicidal NETs”, which proceed in 3–4 h, and induce DNA release concomitantly by rupturing neutrophils to cause cell death (NETosis); and (2) “vital NETs”, which release DNA via vesicles into the extracellular space within 60 min, without causing cell death [2,23]. Notably, the term “NETosis” is applicable only when experimental evidence clearly supports cell death upon NETting [24]. While NET formation is elicited via various signaling pathways involving ROS production [25], the two types of NETs are mediated by different sources of ROS. The Raf-MEK-ERK pathway stimulates NADPH oxidase-mediated ROS production in the process of suicidal NETs [26], whereas mitochondrial ROS is mainly required in vital NETs [21,27]. Chromatin decondensation associated with fragmentation of the nucleus is an important step that releases DNA into the extracellular spaces. MPO and proteases, particularly NE, translocate from azurophilic granules to the nucleus to promote disintegration of the chromatin [28], leading to histone degradation [29]. Gasdermin D is a pore-forming protein that was initially identified as a crucial factor for pyroptotic cell death of macrophages [30,31]. NE-dependent cleavage of gasdermin D activates itself, which in turn plays a pivotal role in suicidal NETs by expanding granules and nucleus, and eventually ruptures the plasma membrane [32,33].

3. Detection and Analysis of Protein Citrullination

DNA strands released from neutrophils are decorated by proteins derived from the cytoplasm, azurophil granules, and nuclei. Intracellular ROS production activates peptidylarginine deiminase 4 (PAD4), which catalyzes the posttranslational modification of positively charged arginine residues of histones to neutral citrulline residues. Previous studies have demonstrated the necessity of PAD4 activity for NET formation, whereas most recent studies that have compared the process of NET
formation in mouse and human neutrophils, in addition to HL-60-derived neutrophils, have revealed that PAD4 enzymatic activity is crucial for efficient DNA decondensation [34,35].

Because citrullinated histones are considered as biologically and pathophysiologically relevant markers for NET formation, sensitive and accurate detection of citrullinated proteins is crucial for investigation. Although immunological detection is commonly performed for this purpose, notably, antibodies against citrullinated histones vary remarkably [36]. Moreover, besides citrullinated histones, the citrullinated proteins generated during NET development are poorly understood owing to limited availability of antibodies against different citrullinated proteins [24].

Mass spectrometry (MS) effectively analyzes posttranslational modifications without using specific antibodies. Recent developments in MS-based analyses have provided few methods to detect citrullinated proteins. It is difficult to detect specific citrullinated residues in proteins using conventional MS/MS analyses because the technique should be able to detect minute differences in the molecular mass between arginine and citrulline, which is only 0.98 Da; however, citrulline residues release an isocyanidine group via fragmentation reaction during MS/MS analysis. Thus, citrulline residues in a protein can be efficiently identified by detecting a 43 Da difference in the molecular mass, which corresponds to the neutral loss of the isocyanidine group (Figure 1a,b) [37].

Figure 1. Structures of the citrulline residue and the methods to identify citrullinated proteins using tandem mass spectrometry (MS/MS). (a) Deimination of an arginine residue by peptidylarginine deiminase (PAD) 4 produces a citrulline residue. In MS/MS analysis, fragmentation of citrulline releases an isocyanic acid group that causes a 43 Da loss, which can be utilized in a neutral loss scan to detect citrulline residues. (b) MS/MS spectra of citrullinated peptides by neutral loss scan can determine the amino acid sequences and positions of citrulline residues. In the secondary MS stage, fragmentation of the peptide occurs at any peptide bond in addition to neutral loss of citrulline residue. The m/z signals correspond to fragments with different numbers of amino acid residues; the fragment ions containing citrulline can be identified as paired spectra with a 43 Da difference. (c) Phenylglyoxal probes readily react with citrulline residues to form stable adducts under acidic conditions. These probes contain the structural moiety of rhodamine or biotin to assist specific detection or purification.
An alternative method utilizing a chemical labeling technique has been developed using phenylglyoxal (PG)-based probes that react with citrulline under acidic conditions (Figure 1c) [38]. Presently, two types of PG-based reagents are available: (1) rhodamine-PG, which is used for 2D-PAGE to visualize proteins containing citrulline residues [39], and (2) biotinylated-PG, which is used to enrich citrullinated peptides or proteins. This technique has revealed that numerous proteins comprising citrullinated residues occur in the synovial fluid and synovial tissue of rheumatoid arthritis, where the major citrullinated proteins are serine protease inhibitors such as antiplasmin, antithrombin, tissue plasminogen activator inhibitor, C1 inhibitor, and nicotinamide N-methyltransferase [40].

Most recently, a proteomic approach successfully elucidated a mechanistic link between PAD4-mediated citrullination of proteins and disease conditions [41]. A disintegrin-like and metalloproteinase with thrombospondin type 1 motif 13 (ADAMTS13) is a specific protease for von Willebrand factor (vWF), known to cause thrombotic thrombocytopenic purpura [42]. vWF, a glycoprotein produced by endothelial cells (ECs), forms multimers and binds to collagen and Factor VIII, thus supporting platelet binding to the wound sites. vWF has been elucidated as one of the key factors in the development of NET-mediated endothelial damage and formation of thrombosis. Venous thrombi are characterized by red clots enriched with erythrocytes, because erythrocyte binding to vWF is promoted upon reduction of shear stress [43]. PAD4 released from NET-forming neutrophils citrullinates ADAMTS13; the modified ADAMTS13 loses its proteolytic activity against vWF, leading to the formation of thrombi after vessel injury via accumulation of platelets [41].

4. NET-Related Receptors

Membrane receptor-mediated signaling pathways lead to NET formation via ROS production and PAD4 activation [25]. In general, toll-like receptors (TLRs) on the plasma membrane of neutrophils play distinctive roles in NET formation in the presence of bacterial pathogen-derived stimuli, including lipopolysaccharides [25].

The receptor for advanced glycation end products (RAGE) is expressed on human neutrophils [44]. High-mobility group box 1 (HMGB1), a DNA-binding protein secreted from macrophages and monocytes, which acts as a damage-associated molecular pattern (DAMP) to mediate thrombosis [45], is expressed on activated platelets. It has been reported that binding of HMGB1 to RAGE on neutrophils induces NET formation [44].

Fcγ receptors expressed on PMNs participate in the induction of ROS production as well as recognition of antibody-opsonized pathogens [46]. The immune complex increases NET formation in murine neutrophils expressing human FcγRIIa (CD32a), but not FcγRIIIB (CD16b) [47]; however, among the antibody receptors expressed by human neutrophils, only FcγRIIIB (CD16b) is responsible for NET formation in response to cross-linking antibodies [48]. Experimental differences, including cell types and stimulants, may be responsible for these differences in findings. Interestingly, TLR7/8 activation leads to proteolytic cleavage of FcγRIIa, thereby shifting neutrophils from phagocytosis of immune complexes to NET formation [49]. Clinically relevant evidence has revealed that neutrophils from patients with systemic lupus erythematosus (SLE) demonstrate similar cleavage of FcγRIIa related to that of neutrophil activation [49].

5. NETs and Cardiovascular Diseases

Several studies regarding the pathophysiological roles of NETs have elucidated the implication of NETs [50] with coronary artery [51,52] and venous thrombosis [53]. Immunothrombosis and NET-induced thrombosis are important and widely studied phenomena [54–56]. Plaque rupture and plaque erosion are two major causes of atherothrombosis. Plaques prone to rupture are characterized by a large lipid core, thin fibrous cap, and numerous macrophages, but few smooth muscle cells (SMCs), which form red fibrin-rich thrombi. Plaque erosion, which causes white platelet-rich thrombi, is associated with enriched collagen, abundant SMCs, and little accumulation of lipids and foam cells [57] (Figure 2). Neutrophils infiltrate culprit lesions, including both ruptured and eroded plaques [58],
via NET formation [59]. By activating neutrophils, circulating MPO levels are increased in patients with acute coronary syndrome [60]. Lipid-lowering pharmacotherapy with statins reduces plasma cholesterol levels and suppresses lipid accumulation in the lesions, thus exerting stabilizing effects on rupture-prone atherosclerotic plaques with reduced inflammation in the vascular tissue [57,61–63]; however, a remarkable number of patients have experienced cardiovascular events even after achieving a marked reduction in their cholesterol levels by statin therapy; accordingly, the underlying mechanism for superficial erosion has gained immense attention [64]. Presently, NETs are regarded as pivotal contributors in the formation of thrombi during superficial erosion [65,66]. This is in accordance with the observations that MPO levels in plasma and the density of MPO-positive cells in thrombi are elevated in acute coronary disease patients with eroded culprit plaques, but not in patients with ruptured culprit plaques [67–69].

Figure 2. Two major lesions that lead to thrombus formation: (a) plaque rupture and (b) plaque erosion—are illustrated. (a) A vulnerable plaque is characterized by a large lipid core covered by a thin fibrous cap. When the fibrous cap is ruptured, red thrombus is produced. (b) A plaque erosion is characterized by a thickened intima enriched with smooth muscle cells (SMCs) and collagen fibers. When endothelial cells are injured, white-platelet-rich thrombus is produced.

NETs have been implicated in metabolic abnormalities such as diabetes. Neutrophils isolated from type 1 and type 2 diabetes are sensitive to NET formation, and the accelerated NETs impair wound healing [19]. Hyperglycemia is correlated with elevated white blood cells and reduced high-density lipoprotein (HDL) cholesterol levels. In diabetic mice, raising the levels of functional HDL, which accepts cholesterol from peripheral tissues, leads to regression of atherosclerosis, associated with decreased plaque inflammation and reduced NET formation in the plaque [70].

The mechanistic link between NET formation and atherosclerosis/thrombosis has been widely investigated. NETs evoke inflammatory responses of immune cells to upregulate inflammatory cytokines [71]. NETs and their components not only damage ECs directly [72,73], but also trigger activation of ECs to form a scaffold, leading to thrombosis. In pathophysiological conditions, including vascular diseases, ECs lose their endothelial phenotype and then acquire a mesenchymal phenotype, which is characterized by the expression of fibroblastic markers [74]. Endothelial-to-mesenchymal transition (EndMT) is involved in the progression of atherosclerosis [74–76]. In general, NETs are internalized into ECs through RAGE via clathrin-dependent endocytosis; however, when excess amounts of NETs remain on the extracellular surface, it induces EndMT of ECs to loosen cell–cell contact, in which NE acts as a proteolytic enzyme of VE-cadherin [77].
6. The Impact of Modified LDL and Its Components on Vascular Cells

Qualitative abnormality of LDL in circulation as well as an imbalance in LDL-cholesterol levels increase the risk of CVDs [78]. Lipoprotein components are susceptible to various modifications through enzymatic and non-enzymatic reactions. Among the lipoprotein components, lipids are the primary targets of oxidation reactions. OxLDL formation proceeds through preferential oxidation of lipid components containing a polyunsaturated fatty acid moiety. During phospholipid oxidation (PLs), the following three types of products are generated. First, unsaturated fatty acids at the sn-2 position of PLs are oxidized to form hydroxy, hydroperoxy, or keto groups. Second, long-chain oxidized fatty acids at the sn-2 position of PLs are cleaved to form short-chain products containing aldehyde or carboxylic acids. Third, the short-chain acyl group at the sn-2 position of PLs is hydrolyzed to form lysophospholipids (lysoPLs) [79]. Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor-acetylhydrolase, plays a crucial role in producing large amounts of lysoPLs in LDL [80]. Spontaneous deacylation of oxidized PLs under physiological conditions is also a possible route for the production of lysoPLs [81]. Subsequently, lipid peroxidation products, including malondialdehyde and 4-hydroxynonenal, act on amino groups in protein components [82]. Notably, several LDL subfractions exert stronger pathogenic effects, which are generated by posttranslational modification or changes in the ratio of lipid to protein components. These newly generated products can act as oxidation-specific epitopes to trigger various inflammatory responses mediated by various scavenger receptors [6].

To date, several types of in vitro modified LDL, including copper-induced oxLDL, acetylated LDL, aggregated LDL, and enzymatically modified LDL (E-LDL), have been investigated to assess their effects on vascular cells [83]. E-LDL, prepared in vitro using trypsin and cholesterol esterase without oxidation of lipids, presents higher bioactivity than copper-induced oxLDL in foam cell formation of SMCs [84]. E-LDL was postulated to be produced by the presence of proteases in atherosclerotic lesions, such as urokinase-type plasminogen activator, matrix metalloproteinase-2 (MMP-2), and MMP-9 [85]; moreover, it has been immunohistochemically detected in human atherosclerotic lesions [85,86]. E-LDL upregulates the expression of IL-8 [87] and adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), platelet endothelial cell adhesion molecule-1, P-selectin, and E-selectin in ECs, which enhance the adhesion and transmigration of monocytes and T-lymphocytes [88]. E-LDL is incorporated in vascular SMCs by micropinocytosis and upregulates the expression of lectin-like oxLDL receptor 1 (LOX-1) to increase the uptake of oxLDL [89]. E-LDL also increases ICAM-1 expression in aortic SMCs [88]. Interestingly, E-LDL reveals potent cytotoxicity on PMNs; the free fatty acids present in E-LDL play a causative role in this toxicity. The toxicity of oxLDL is mimicked by linoleic acid, oleic acid, or arachidonic acid, and is abrogated by coincubation with albumin [90]. This study demonstrated that direct perturbation of the cell membrane of PMNs with fatty acids may cause cytotoxicity and lead to PMN death, predominantly by necrosis, as the apoptotic markers were not detected in the study. There is a possibility that NETs are involved in E-LDL-induced cell death of PMNs.

The production of oxidized lipids and subsequent protein adducts contributes to an increase in the electronegativity of lipoprotein particles. Electronegative LDL (LDL(−)) is a naturally occurring LDL subfraction that is postulated to be enriched with negatively charged particles [91]. LDL(−) contains non-LDL apolipoproteins such as apolipoprotein A-I and apo A [92] as well as aggregated LDL with phospholipase C-like and sphingomyelinase activities [93,94]. LDL(−) has a higher content of diacylglycerol, ceramide, monoacylglycerol, and phosphorylcholine [93]. Moreover, LDL(−) is preferentially associated with Lp-PLA2 [95,96] and comprises more lysoPLs and nonesterified fatty acids than native LDL [97]. LDL(−) exerts highly proatherogenic effects by activating various cells [98] that are mediated by LOX-1 and PAF receptors. These two receptors mediate LDL(−)-induced endothelial apoptosis [99,100]. The binding of LDL(−) to ECs via LOX-1 mediates LDL(−)-induced premature vascular endothelial senescence [101]. Furthermore, LDL(−) also induces aggregation of platelets through the LOX-1 and PAF receptors, which promote platelet adhesion to ECs and thrombogenic
state [102]. Interestingly, LDL(−) enhances the formation of triglyceride (TG)-rich lipid droplets in macrophages and releases more cytokines than copper-induced oxLDL [103].

Most recently, we reported the characterization of in vivo-oxLDL in the LDL(−) fraction released from atherosclerotic plaques of patients with acute myocardial infarction (AMI) [104]. In vivo oxLDL was modified with oxidized phosphatidylcholine (oxPC) and oxidized HDL [105]. While oxLDL, recognized using the anti-oxPC antibody, was detected in several fractions including LDL(−) fractions, oxLDL in LDL(−) was threefold higher in patients with AMI than in healthy subjects [104]. Our observation is in accordance with previous studies that reported an increase in oxLDL levels in plasma samples from patients with AMI. Proteins in LDL(−) contain apoB conjugated with oxPC. Such a modification could cause increased resistance to lysosomal hydrolysis in foam cells [106]. Moreover, LDL(−) is enriched with HDL-like particles containing apoA-I heavily modified with acrolein adducts. Electron microscopic analysis revealed that LDL(−) contains heterogeneous and aggregated subpopulations with small-sized particles, similar to HDL [104].

These results imply that small dense LDL (sdLDL) could be related to in vivo oxLDL, which has been reported as another atherogenic subfraction of LDL with high oxidative susceptibility [107] and a strong association with a future risk for coronary heart diseases [108,109]. Elevated levels of TG-rich VLDL in plasma cause increased synthesis of TG-rich LDL and subsequent extensive hydrolysis of core TG by hepatic lipase, which in turn leads to increased formation of sdLDL particles [110,111]. Indeed, elevated sdLDL levels are associated with increased postprandial large VLDL and remnant-like particles in patients with AMI [112]. The metabolic rate of sdLDL increases owing to its decreased affinity for LDL receptor, resulting in delayed hepatic clearance [113]. Furthermore, enhanced binding of sdLDL to extrahepatic tissues is mediated by increased binding to proteoglycans of the cell surface [114]. Foam cell formation in THP-1 macrophages, induced by stimulation with sdLDL, is associated with a remarkable increase in mRNA and protein expression of LOX-1 via TLR4 [107], thereby indicating that sdLDL may upregulate signal transduction through TLR4.

7. Modified LDL and NET Formation

OxLDL acts as a DAMP and triggers sterile inflammatory responses to promote CVDs [6]. Infiltration of neutrophils into arteries during the early stages of atherosclerosis has been observed in hypercholesterolemic mice [115]. Numerous studies, on mice and humans, have provided evidence for the contribution of neutrophils to early atherosclerosis [116,117]. We have demonstrated the appearance of oxLDL in vascular tissues and in circulation even prior to atherosclerotic lesion development in apoE-KO mice [118]. These findings prompted us to examine whether oxLDL influences NET formation and subsequent endothelial inflammatory responses. PMA-induced NET formation in both HL-60-derived neutrophils and human PMNs is remarkably accelerated upon coincubation with oxLDL, but not with native LDL [119]. Moreover, extracellular components, after induction of NET formation by PMA with oxLDL, are capable of inducing morphological changes and MMP-1 expression in human aortic ECs (Figure 3). Presumably, neutrophils may play a pivotal role in the early stages of atherogenesis through the cooperative actions of oxLDL.

Intriguingly, NET-induced activation of human aortic ECs is enhanced upon coincubation with native LDL, suggesting that MPO and proteases released from neutrophils upon NET formation could act on native LDL and induce oxidative modification and/or degradation of LDL to produce modified proinflammatory LDL [11]. These phenomena, induced by the coexistence of NETs and native LDL or oxLDL, correspond to enhanced EndMT caused by the excess phagocytic capacity of ECs [77]. One possibility is that the cooperative action of oxLDL and NETs on ECs induces EndMT and subsequent neovascularization, which leads to atherosclerotic lesion formation [120].
Figure 3. Schematic diagram of a feed-forward cascade that drives the neutrophil extracellular trap (NET)-induced endothelial inflammatory response. OxLDL strongly accelerates NET formation of activated neutrophils, while the same NET formation-inducing effect of oxLDL on resting neutrophils has not been observed. MPO and proteases released from neutrophils by NET formation could act on native low-density lipoprotein (LDL) to facilitate modification of LDL. Coexistence of NETs and oxLDL or native LDL promotes endothelial inflammation to cause cell elongation and enhanced MMP-1 production in endothelial cells [119]. MPO: myeloperoxidase, MMP-1: matrix metalloproteinase-1.

Recently, a unique regulatory mechanism of lipoprotein-mediated vWF degradation has been described. LDL, but not HDL, has the ability to bind vWF and accelerate proteolytic cleavage of vWF by ADAMTS13 in a concentration-dependent manner under shear stress; however, oxLDL competitively inhibits vWF proteolysis associated with native LDL. Furthermore, native LDL, but not oxLDL, inhibits adhesion of platelets to vWF on ECs under flow [121]. NET formation also inhibits the proteolytic activity of ADAMTS13 via PAD4-mediated citrullination, as described earlier [41]. Considering that vWF functions as a scaffold for NETs, thrombosis, and platelets, these data indicate that oxLDL may enhance NET-mediated thrombosis formation via direct interaction with vWF (Figure 4).

Awasthi et al. reported the accelerating effect of oxLDL on NET formation in human neutrophils and proposed that components of oxLDL, such as oxPC and lysophosphatidylcholine, are responsible for NET formation [122]. Moreover, oxPLs derived from ether-linked phosphatidylethanolamine and phosphatidylcholine induce NET formation [123]. Furthermore, lipid extracts from LDL(−) of hypercholesterolemic patients induce calcium influx in human neutrophils, which is completely suppressed upon treatment with recombinant Lp-PLA2 [100], indicating that LDL(−) might contain bioactive oxPCs that affect NET formation. It has been reported that TLR2/6 acts synergistically on NET formation upon stimulation with oxLDL [122]. In addition, RAGE has been reported to mediate oxLDL-induced proinflammatory conditions in LDL receptor knockout mice [124]. RAGE-mediated neutrophil dysfunction [125] and HMGB1 expressed on platelets induce NET formation via RAGE [44]. These data suggest that oxLDL and oxidized lipids may initiate NET formation, and these products may act on neutrophils through TLRs and/or RAGE; however, the involvement of other scavenger receptors remains to be elucidated.
Figure 4. The synergistic actions of NET formation and oxLDL production presumably cause a proatherothrombotic status on the vascular endothelium. (a) PAD4 secreted by NET formation mediates citrullination of ADAMTS13, which inhibits the proteolytic activity of ADAMTS13 against von Willebrand factor (vWF), leading to increased vWF-platelet string formation on the endothelium [41]. (b) LDL, identified as a novel vWF-binding partner, accelerates the proteolytic cleavage of ultra-large vWF by ADAMTS13 under shear stress, and inhibits adhesion of platelets to ultra-large vWF. OxLDL, having lower ability to enhance proteolytic activity of ADAMTS13 than native LDL, competes with native LDL, which in turn increases platelet adhesion to ultra-large vWF, which could cause thrombus formation rich in vWF, platelets, and DNA [121].

In terms of sphingolipids, an endogenous increase in ceramide has been implicated in the process of NET formation [126,127]. Interestingly, anacardic acid, a natural product extracted from cashew nut shells, stimulates neutrophils via sphingosine-1-phosphate (S1P) receptor 4 to induce NET formation [128]. Histone citrullination in mouse bone marrow neutrophils increases in a mouse model of fatty liver disease, in which the mice were fed a methionine-choline-deficient and high-fat diet, and a DNase injection attenuated the fatty liver of the mice [129]. This mouse fatty liver model suggested that hepatic S1P induces NET formation via S1P receptor 2, which plays a pivotal role in shifting the cell death of murine neutrophils from apoptosis to NETosis [129]. Considering that LDL(−) contains higher amounts of ceramides than normal LDL [93], and that HDL serves as a carrier of S1P [130], the role of lipoprotein sphingolipids would be of interest for future studies.

8. Significance of OxLDL in Autoimmune Diseases

SLE is an autoimmune disease associated with a high risk of CVDs, and neutrophils contribute to the pathogenesis of vascular damage via enhanced NET formation [131]. Low-density neutrophils (LDNs) are a unique subtype of neutrophils separated using gradient ultracentrifugation, which are
increased in patients with various diseases, including autoimmune disease, cancer, and sepsis [132]. This subset of neutrophils is presumed to be in the activated state and serves as one of the key players in SLE [133]. LDNs from patients with SLE display distinct gene expression profiles in normal neutrophils, with higher expression of immunostimulatory and bactericidal proteins [134]. LDNs from patients with SLE exhibit higher susceptibility to NET formation and increased capacity to kill ECs through NET formation [134]. In fact, circulating oxLDL levels increase in patients with SLE, where oxLDL, but not native LDL, forms a complex with β2-glycoprotein I (β2-GPI). Such a complex could induce the production of proatherogenic anti-oxLDL/β2-GPI autoantibodies [135,136]. β2-GPI is a glycoprotein that specifically binds to oxidized products of phospholipids and cholesteryl esters and acts as a major target antigen for antiphospholipid antibodies developed in autoimmune diseases, including antiphospholipid syndrome and SLE [137]. Interestingly, the anti-β2-GPI/β2-GPI immune complex acts on neutrophils to induce NET formation associated with platelet aggregation, leading to enhanced thrombus formation [138]. These data indicate that the oxLDL/β2-GPI complex and/or its immune complex may also contribute to the development of vascular complications in SLE through upregulation of NET formation. It is noteworthy that LDNs express higher levels of LOX-1 in patients with SLE compared with the normal subjects [139]. Thus, presumably, LOX-1 may play a pivotal role in eliciting NET formation by stimulating neutrophils with oxLDL.

9. Conclusions

NET formation is induced by various stimulants, including exogenous DAMPs, in addition to numerous proinflammatory cytokines. Multiple receptors recognizing DAMPs, such as TLRs and RAGE, mediate NET formation by activating intracellular signal transduction. OxLDL and oxidized lipids induce and enhance NET formation. Considering that oxLDL and oxidized lipids are produced in the circulation, it is likely that oxLDL and oxidized lipids behave like endogenous DAMPs to affect neutrophil activation. Enzymes released from neutrophils after NET formation could modify LDL and HDL, which facilitates further neutrophil activation. Vascular damage through endothelial activation by NET formation leads to the development of atherosclerosis and thrombosis. Although further analysis is necessary, the concept that the synergistic action of oxLDL and neutrophils is linked to accelerated NET formation may provide new insight into the molecular and mechanistic basis of CVDs and aid the development of therapeutic approaches.

Author Contributions: Writing—original draft preparation, T.O.; Writing—review and editing, H.I. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported in part by JSPS KAKENHI (grant numbers 16K08245 and 19K07069).

Acknowledgments: We would like to thank Editage (www.editage.jp) for English language editing.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

NETs neutrophil extracellular traps
DAMPs damage-associated molecular patterns
oxLDL oxidized low-density lipoprotein
CVD cardiovascular disease
MPO myeloperoxidase
ROS reactive oxygen species
NE neutrophil elastase
PMNs polymorphonuclear leukocytes
PMA phorbol myristate acetate
PAD4 peptidylarginine deiminase 4
References

1. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science 2004, 303, 1532–1535. [CrossRef]

2. Castanheira, F.V.S.; Kubes, P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood 2019, 133, 2178–2185. [CrossRef]

3. Sollberger, G.; Tilley, D.O.; Zychlinsky, A. Neutrophil extracellular traps: The biology of chromatin externalization. Dev. Cell 2018, 44, 542–553. [CrossRef] [PubMed]

4. Doring, Y.; Libby, P.; Soehnlein, O. Neutrophil extracellular traps participate in cardiovascular diseases: Recent experimental and clinical insights. Circ. Res. 2020, 126, 1228–1241. [CrossRef]

5. Itabe, H.; Obama, T.; Kato, R. The dynamics of oxidized LDL during atherogenesis. J. Lipids 2011, 2011, 418313. [CrossRef]

6. Binder, C.J.; Papac-Milicevic, N.; Witztum, J.L. Innate sensing of oxidation-specific epitopes in health and disease. Nat. Rev. Immunol. 2016, 16, 485–497. [CrossRef]

7. Polacek, D.; Byrne, R.E.; Fless, G.M.; Scanu, A.M. In vitro proteolysis of human plasma low density lipoproteins by an elastase released from human blood polymorphonuclear cells. J. Biol. Chem. 1986, 261, 2057–2063. [PubMed]

8. Polacek, D.; Byrne, R.E.; Scanu, A.M. Modification of low density lipoproteins by polymorphonuclear cell elastase leads to enhanced uptake by human monocyte-derived macrophages via the low density lipoprotein receptor pathway. J. Lipid Res. 1988, 29, 797–808.

9. Manda-Handzlik, A.; Bystrzycka, W.; Wachowska, M.; Sieczkowski, S.; Stelmaszczyk-Emmel, A.; Demkow, U.; Ciepiela, O. The influence of agents differentiating HL-60 cells toward granulocyte-like cells on their ability to release neutrophil extracellular traps. Immunol. Cell. Biol. 2018, 96, 413–425. [CrossRef]

10. Hoppenbrouwers, T.; Autar, A.S.A.; Sultan, A.R.; Abraham, T.E.; van Cappellen, W.A.; Houtsomuller, A.B.; van Wamel, W.J.B.; van Beusekom, H.M.M.; van Neck, J.W.; de Maat, M.P.M. In vitro induction of NETosis: Comprehensive live imaging comparison and systematic review. PLoS ONE 2017, 12, e0176472. [CrossRef]
11. Kahlenberg, J.M.; Carmona-Rivera, C.; Smith, C.K.; Kaplan, M.J. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. *J. Immunol.* 2013, 190, 1217–1226. [CrossRef]  
12. Silvestre-Roig, C.; Braster, Q.; Wichapong, K.; Lee, E.Y.; Teulon, J.M.; Berrebeha, N.; Winter, J.; Adrover, J.M.; Santos, G.S.; Froese, A.; et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature* 2019, 569, 236–240. [CrossRef]  
13. Yousefi, S.; Mihalache, C.; Kozlowski, E.; Schmid, I.; Simon, H.U. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ.* 2009, 16, 1438–1444. [CrossRef] [PubMed]  
14. Bertin, F.R.; Rys, R.N.; Mathieu, C.; Laurance, S.; Lemarie, C.A.; Blostein, M.D. Natural killer cells induce neutrophil extracellular trap formation in venous thrombosis. *J. Thromb. Haemost.* 2019, 17, 403–414. [CrossRef] [PubMed]  
15. Chatfield, S.M.; Grebe, K.; Whitehead, L.W.; Rogers, K.L.; Nebl, T.; Murphy, J.M.; Wicks, I.P. Monosodium urate crystals generate nuclease-resistant neutrophil extracellular traps via a distinct molecular pathway. *J. Immunol.* 2018, 200, 1802–1816. [CrossRef]  
16. Schauer, C.; Janko, C.; Munoz, L.E.; Zhao, Y.; Kienhofer, D.; Frey, B.; Lell, M.; Manger, B.; Rech, J.; Naschberger, E.; et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytoplasmics. *Nat. Med.* 2014, 20, 511–517. [CrossRef]  
17. Warnatsch, A.; Ioannou, M.; Wang, Q.; Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. *Science* 2015, 349, 316–320. [CrossRef]  
18. Menegazzo, L.; Cicliot, S.; Poncina, N.; Mazzucato, M.; Persano, M.; Bonora, B.; Albiero, M.; Vigili de Kreutzenberg, S.; Avogaro, A.; Fadini, G.P. NETosis is induced by high glucose and associated with type 2 diabetes. *Acta Diabetol.* 2015, 52, 497–503. [CrossRef]  
19. Wong, S.L.; Demers, M.; Martinod, K.; Gallant, M.; Wang, Y.; Goldfine, A.B.; Kahn, C.R.; Wagner, D.D. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat. Med.* 2015, 21, 815–819. [CrossRef] [PubMed]  
20. Wang, L.; Zhou, X.; Yin, Y.; Mai, Y.; Wang, D.; Zhang, X. Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy. *Front Immunol.* 2018, 9, 3076. [CrossRef]  
21. Hosseinzadeh, A.; Thompson, P.R.; Segal, B.H.; Urban, C.F. Nicotine induces neutrophil extracellular traps. *J. Leuko Biol.* 2016, 100, 1105–1112. [CrossRef]  
22. Lee, J.; Luria, A.; Rhodes, C.; Raghu, H.; Lingampalli, N.; Sharpe, O.; Rada, B.; Sohn, D.H.; Robinson, W.H.; Sokolove, J. Nicotine drives neutrophil extracellular traps formation and accelerates collagen-induced arthritis. *Rheumatology (Oxford)* 2017, 56, 644–653. [CrossRef]  
23. Jorch, S.K.; Kubes, P. An emerging role for neutrophil extracellular traps in noninfectious disease. *Nat. Med.* 2017, 23, 279–287. [CrossRef] [PubMed]  
24. Boeltz, S.; Amini, P.; Anders, H.J.; Andrade, F.; Bilyy, R.; Chatfield, S.; Cichon, I.; Clancy, D.M.; Desai, J.; Dumych, T.; et al. To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps. *Cell Death Differ.* 2019, 26, 395–408. [CrossRef]  
25. Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. *Nat. Rev. Immunol.* 2018, 18, 134–147. [CrossRef]  
26. Hakkim, A.; Fuchs, T.A.; Martinez, N.E.; Hess, S.; Prinz, H.; Zychlinsky, A.; Waldmann, H. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. *Nat. Chem. Biol.* 2011, 7, 75–77. [CrossRef] [PubMed]  
27. Douda, D.N.; Khan, M.A.; Grasemann, H.; Palaniyar, N. SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. *Proc. Natl. Acad. Sci. USA* 2015, 112, 2817–2822. [CrossRef]  
28. Papayannopoulos, V.; Metzler, K.D.; Hakkim, A.; Zychlinsky, A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J. Cell Biol.* 2010, 191, 677–691. [CrossRef]  
29. Erpenbeck, L.; Schon, M.P. Neutrophil extracellular traps: protagonists of cancer progression? *Oncogene* 2017, 36, 2483–2490. [CrossRef]  
30. Shi, J.; Zhao, Y.; Wang, K.; Shi, X.; Wang, Y.; Huang, H.; Zhuang, Y.; Cai, T.; Wang, F.; Shao, F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* 2015, 526, 660–665. [CrossRef]
31. Kayagaki, N.; Stowe, I.B.; Lee, B.L.; O’Rourke, K.; Anderson, K.; Warming, S.; Cuellar, T.; Haley, B.; Roose-Girma, M.; Phung, Q.T.; et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* 2015, 526, 666–671. [CrossRef] [PubMed]

32. Chen, K.W.; Monteleone, M.; Boucher, D.; Sollberger, G.; Ramnath, D.; Condon, N.D.; von Pein, J.B.; Broz, P.; Sweet, M.J.; Schroder, K. Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. *Sci. Immunol.* 2018, 3, eaar6676. [CrossRef]

33. Sollberger, G.; Choidas, A.; Burn, G.L.; Habenberger, P.; Di Lucrezia, R.; Kordes, S.; Menninger, S.; Eickhoff, J.; Nussbaumer, P.; Klebl, B.; et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. *Sci. Immunol.* 2018, 3, eaar6689. [CrossRef]

34. Thiam, H.R.; Wong, S.L.; Qiu, R.; Kittisopikul, M.; Vahabikashi, A.; Goldman, A.E.; Goldman, R.D.; Neeli, I.; Radic, M. Current challenges and limitations in antibody-based detection of citrullinated histones. *Front Immunol.* 2016, 7, 528. [CrossRef] [PubMed]

35. Hao, G.; Wang, D.; Gu, J.; Shen, Q.; Gross, S.S.; Wang, Y. Neutral loss of isocyanic acid in peptide CID spectra: a novel diagnostic marker for mass spectrometric identification of protein citrullination. *J. Am. Soc. Mass Spec.* 2009, 20, 723–727. [CrossRef] [PubMed]

36. Neeli, I.; Sorvillo, N.; Mizurini, D.M.; Coxon, C.; Martinod, K.; Tilvawala, R.; Cherpokova, D.; Salinger, A.J.; Seward, R.J.; Weerapana, E.; Thompson, P.R. The rheumatoid arthritis-associated citrullinome. *Cell Chem. Biol.* 2018, 25, 691–704. [CrossRef]

37. Joly, B.S.; Coppo, P.; Veyradier, A. Thrombotic thrombocytopenic purpura. *Blood* 2019, 124, 3213–3223. [CrossRef] [PubMed]

38. Nguyen, G.T.; Green, E.R.; Mecsas, J. Neutrophils to the ROScue: Mechanisms of NADPH oxidase activation and bacterial resistance. *Front Cell Infect. Microbiol.* 2017, 7, 373. [CrossRef]

39. Chen, K.; Nishi, H.; Travers, R.; Tsuibo, N.; Martinod, K.; Wager, D.D.; Stan, R.; Croce, K.; Mayadas, T.N. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIIB in vivo. *Blood* 2012, 120, 4421–4431. [CrossRef]

40. Aleman, O.R.; Mora, N.; Cortes-Vieyras, R.; Uribé-Querol, E.; Rosales, C. Differential use of human neutrophil FcγRIIa receptors for inducing neutrophil extracellular trap formation. *J. Immunol. Res.* 2016, 2016, 290834. [CrossRef]

41. Lood, C.; Arve, S.; Ledbetter, J.; Elkton, K.B. TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcγRIIa. *J. Exp. Med.* 2017, 214, 2103–2119. [CrossRef]

42. Kapoor, S.; Opneja, A.; Nayak, L. The role of neutrophils in thrombosis. *Thromb. Res.* 2018, 170, 87–96. [CrossRef]
51. Perttiwi, K.R.; van der Wal, A.C.; Pabittei, D.R.; Mackaaij, C.; van Leeuwen, M.B.; Li, X.; de Boer, O.J. Neutrophil Extracellular Traps Participate in All Different Types of Thrombotic and Haemorrhagic Complications of Coronary Atherosclerosis. *Thromb. Haemost.* 2018, 118, 1078–1087. [CrossRef]
52. Mangold, A.; Alias, S.; Scherz, T.; Hofbauer, T.; Jakowitsch, J.; Panzenbock, A.; Simon, D.; Laimer, D.; Bangert, C.; Kammerlander, A.; et al. Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size. *Circ. Res.* 2015, 116, 1182–1192. [CrossRef]
53. Savchenko, A.S.; Martinod, K.; Seidman, M.A.; Wong, S.L.; Borisoff, J.I.; Piazza, G.; Libby, P.; Goldhaber, S.Z.; Mitchell, R.N.; Wagner, D.D. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. *J. Thromb. Haemost.* 2014, 12, 860–870. [CrossRef] [PubMed]
54. Fuchs, T.A.; Brill, A.; Duerschmied, D.; Schatzberg, D.; Panzenbock, A.; Simon, D.; Laimer, D.; Wakefield, T.W.; Hartwig, J.H.; Wagner, D.D. Extracellular DNA traps promote thrombosis. *Proc. Natl. Acad. Sci. USA* 2010, 107, 15880–15885. [CrossRef] [PubMed]
55. Massberg, S.; Grahl, L.; von Bruehl, M.L.; Manukyan, D.; Pfeiler, S.; Goosmann, C.; Brinkmann, V.; Lorenz, M.; Bidzhekov, K.; Khandagale, A.B.; et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat. Med.* 2010, 16, 887–896. [CrossRef] [PubMed]
56. Brill, A.; Fuchs, T.A.; Savchenko, A.S.; Thomas, G.M.; Martinod, K.; De Meyer, S.F.; Bhandari, A.A.; Wagner, D.D. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J. Thromb. Haemost.* 2012, 10, 136–144. [CrossRef]
57. Quillard, T.; Franck, G.; Mason, T.; Folco, E.; Libby, P. Mechanisms of erosion of atherosclerotic plaques. *Curr. Opin. Lipidol.* 2017, 28, 434–441. [CrossRef]
58. Naruko, T.; Ueda, M.; Haze, K.; van der Wal, A.C.; van der Loos, C.M.; Itoh, A.; Komatsu, R.; Ikura, Y.; Ogami, M.; Shimada, Y.; et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. *Circulation* 2002, 106, 2894–2900. [CrossRef]
59. Megens, R.T.; Vijayan, S.; Lievens, D.; Doring, Y.; van Zandvoort, M.A.; Grommes, J.; Weber, C.; Soehnlein, O.; Itoh, A.; Haze, K.; et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat. Med.* 2010, 16, 887–896. [CrossRef] [PubMed]
60. Brill, A.; Fuchs, T.A.; Savchenko, A.S.; Wong, S.L.; Borissoff, J.I.; Joosen, I.A.; Versteylen, M.O.; Libby, P.; Goldhaber, S.Z.; Mitchell, R.N.; Wagner, D.D. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. *J. Thromb. Haemost.* 2014, 12, 860–870. [CrossRef] [PubMed]
61. Quillard, T.; Araujo, H.A.; Franck, G.; Schwart, E.; Sukhova, G.; Libby, P. TLR2 and neutrophils potentiate endothelial stress, apoptosis, and detachment: implications for superficial erosion. *Circ. Res.* 2015, 116, 1182–1192. [CrossRef] [PubMed]
62. Zhao, X.Q.; Dong, L.; Hatsukami, T.; Phan, B.A.; Chu, B.; Moore, A.; Lane, T.; Neradilek, M.B.; Polissar, N.; Libby, P. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J. Thromb. Haemost.* 2012, 10, 136–144. [CrossRef]
63. Ten Cate, H.; Hofstra, L.; et al. Elevated levels of circulating DNA and chromatin are independently associated with cardiovascular events in patients with acute coronary syndrome. *Circulation* 2013, 168, 2004–2013. [CrossRef]
64. Zhao, X.Q.; Dong, L.; Hatsukami, T.; Phan, B.A.; Chu, B.; Moore, A.; Lane, T.; Neradilek, M.B.; Polissar, N.; Monick, D.; et al. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. *Jacc Cardiovasc. Imag.* 2011, 4, 977–986. [CrossRef]
65. Takarada, S.; Imanishi, T.; Kubo, T.; Tanimoto, T.; Kitabata, H.; Nakamura, N.; Tanaka, A.; Mizukoshi, M.; Akasaka, T. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. *Atherosclerosis* 2009, 202, 491–497. [CrossRef] [PubMed]
66. Jernberg, T.; Hasvold, P.; Henriksen, M.; Hjelm, H.; Thuresson, M.; Janzon, M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. *Euro. Heart J.* 2015, 36, 1163–1170. [CrossRef] [PubMed]
67. Quillard, T.; Araujo, H.A.; Franck, G.; Schwart, E.; Sukhova, G.; Libby, P. TLR2 and neutrophils potentiate endothelial stress, apoptosis, and detachment: implications for superficial erosion. *Circ. Res.* 2015, 116, 1182–1192. [CrossRef] [PubMed]
68. Franck, G.; Mason, T.; Sausen, G.; Salinas, M.; Masson, G.S.; Cole, A.; Beltrami-Moreira, M.; Chatzizisis, Y.; Quillard, T.; Tesmenitsky, Y.; et al. Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion. *Circ. Res.* 2017, 121, 31–42. [CrossRef] [PubMed]
69. Goldmann, B.U.; Rudolph, V.; Rudolph, T.K.; Holke, A.K.; Hillebrandt, M.; Meinerz, T.; Baldus, S. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. *Free Radic. Biol. Med.* 2009, 47, 79–83. [CrossRef] [PubMed]
associated with severe coronary atherosclerosis and a prothrombotic state. *Arter. Thromb. Vasc. Biol.* **2013**, *33*, 2032–2040. [CrossRef]

69. Ferrante, G.; Nakano, M.; Prati, F.; Niccoli, G.; Mallus, M.T.; Ramazzotti, V.; Montone, R.A.; Kolodgie, F.D.; Virmani, R.; Crea, F. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. *Circulation* **2010**, *122*, 2505–2513. [CrossRef]

70. Barret, T.J.; Distel, E.; Murphy, A.J.; Hu, J.; Garshick, M.S.; Ogando, Y.; Liu, J.; Vaisar, T.; Heinecke, J.W.; Berger, J.S.; et al. Apolipoprotein AI promotes atherosclerosis regression in diabetic mice by suppressing myelopoiesis and plaque inflammation. *Circulation* **2019**, *140*, 1170–1184. [CrossRef]

71. Qi, H.; Yang, S.; Zhang, L. Neutrophil Extracellular Traps and Endothelial Dysfunction in Atherosclerosis and Thrombosis. *Front. Immunol.* **2017**, *8*, 928. [CrossRef]

72. Meegan, J.E.; Yang, X.; Beard, R.S., Jr.; Jannaway, M.; Chatterjee, V.; Taylor-Clark, T.E.; Young, S.Y. Citrullinated histone 3 causes endothelial barrier dysfunction. *Biochim. Biophys. Res. Commun.* **2018**, *503*, 1498–1502. [CrossRef]

73. Safarzadeh, M.; Juennemann, C.; Queisser, M.A.; Lochnit, G.; Barreto, G.; Galuska, S.P.; Lohmeyer, J.; Preissner, K.T. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS ONE* **2012**, *7*, e32366. [CrossRef]

74. Evrard, S.M.; Lece, L.; Michelis, K.C.; Nomura-Kitabayashi, A.; Pandey, G.; Purushothaman, K.R.; d’Escamard, V.; Li, J.R.; Hadri, L.; Fujitani, K.; et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. *Nat. Commun.* **2016**, *7*, 11853. [CrossRef] [PubMed]

75. Chen, P.Y.; Qin, L.; Baeyens, N.; Li, G.; Afolabi, T.; Budatha, M.; Tellides, G.; Schwartz, M.A.; Simons, M. Enzyme-modified non-oxidized LDL (ELDL) structures formed in oxidized low-density lipoprotein using LC-MS/MS. *Proteomics* **2018**, 1288, 54–62. [CrossRef] [PubMed]

76. Wesseling, M.; Sakkers, T.R.; de Jager, S.C.A.; Pasterkamp, G.; Goumans, M.J. The morphological and molecular mechanisms of epithelial/endothelial-to-mesenchymal transition and its involvement in atherosclerosis. *Vasc. Pharm.* **2018**, *106*, 1–8. [CrossRef]

77. Pieterse, E.; Rother, N.; Garsen, M.; Hofstra, J.M.; Satchell, S.C.; Hoffmann, M.; Loeven, M.A.; Knaapen, H.K.; van der Heijden, O.W.H.; Berden, J.H.M.; et al. Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition. *Arterioscler. Thromb. Vasc. Biol.* **2017**, *37*, 1371–1379. [CrossRef] [PubMed]

78. Itabe, H.; Kato, R.; Sawada, N.; Obama, T.; Yamamoto, M. The significance of oxidized low-density lipoprotein in body fluids as a marker related to diseased conditions. *Curr. Med. Chem.* **2019**, *26*, 1576–1593. [CrossRef]

79. Lee, J.Y.; Lim, S.; Park, S.; Moon, M.H. Characterization of oxidized phospholipids in oxidatively modified low density lipoproteins by nanoflow liquid chromatography-tandem mass spectrometry. *J. Chromato. A* **2013**, *1288*, 54–62. [CrossRef] [PubMed]

80. Sasabe, N.; Keyamura, Y.; Obama, T.; Inoue, N.; Masuko, Y.; Igarashi, Y.; Aiuchi, T.; Kato, R.; Yamaguchi, T.; Kuwata, H.; et al. Time course changes in phosphatidylcholine profile during oxidative modification of low-density lipoprotein. *Lipids Health Dis.* **2014**, *13*, 48. [CrossRef]

81. Choi, J.; Zhang, W.; Gu, X.; Chen, X.; Hong, L.; Laird, J.M.; Salomon, R.G. Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids. *Chem Res. Toxicol.* **2011**, *24*, 111–118. [CrossRef]

82. Obama, T.; Kato, R.; Masuda, Y.; Takahashi, K.; Aiuchi, T.; Itabe, H. Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. *Proteomics* **2007**, *7*, 2123–2141. [CrossRef]

83. Levitan, I.; Volkov, S.; Subbaiah, P.V. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. *Antioxid. Redox. Signal.* **2010**, *13*, 39–75. [CrossRef]

84. Chellan, B.; Rojas, E.; Zhang, C.; Hofmann Bowman, M.A. Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype. *Sci. Rep.* **2018**, *8*, 11954. [CrossRef]

85. Torzewski, M.; Suriyaphol, P.; Paprotka, K.; Spath, L.; Ochsenhirt, V.; Schmitt, A.; Han, S.R.; Husmann, M.; Gerl, V.B.; Bhakdi, S.; et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. *Arter. Thromb. Vasc. Biol.* **2004**, *24*, 2130–2136. [CrossRef]

86. Torzewski, M.; Klouche, M.; Hock, J.; Messner, M.; Dorweiler, B.; Torzewski, J.; Gabbert, H.E.; Bhakdi, S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. *Arter. Thromb. Vasc. Biol.* **1998**, *18*, 369–378. [CrossRef]
87. Suriyaphol, P.; Fenske, D.; Zahringer, U.; Han, S.R.; Bhakdi, S.; Husmann, M. Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. *Circulation* 2002, 106, 2581–2587. [CrossRef]

88. Klouche, M.; May, A.E.; Hemmes, M.; Messner, M.; Kanse, S.M.; Preissner, K.T.; Bhakdi, S. Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. *Arter. Thromb. Vasc. Biol.* 1999, 19, 784–793. [CrossRef] [PubMed]

89. Bancells, C.; Villegas, S.; Blanco, F.J.; Benitez, S.; Colome, N.; Julve, J.; Sanchez-Quesada, J.L. Proteomic analysis of electronegative low-density lipoprotein. *J. Lipid Res.* 2010, 51, 3508–3515. [CrossRef] [PubMed]

90. Lu, M.; Koschinski, A.; Dersch, K.; Husmann, M.; Bhakdi, S. Hypersusceptibility of neutrophil granulocytes towards lethal action of free fatty acids contained in enzyme-modified atherogenic low density lipoprotein. *Atherosclerosis* 2009, 207, 116–122. [CrossRef]

91. Yang, C.Y.; Raya, J.L.; Chen, H.H.; Chen, C.H.; Abe, Y.; Pownall, H.J.; Taylor, A.A.; Smith, C.V. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. *Arter. Thromb. Vasc. Biol.* 2003, 23, 1083–1090. [CrossRef]

92. Benitez, S.; Canals, F.; Benitez, S.; Colome, N.; Julve, J.; Sanchez-Quesada, J.L. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. *Atherosclerosis* 2004, 177, 299–305. [CrossRef]

93. Gaubatz, J.W.; Gillard, B.K.; Massey, J.B.; Hoogeveen, R.C.; Huang, M.; Lloyd, E.E.; Raya, J.L.; Yang, C.Y.; Pownall, H.J. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). *J. Lipid Res.* 2007, 48, 348–357. [CrossRef]

94. Benitez, S.; Camacho, M.; Arcelus, R.; Vila, L.; Bancells, C.; Ordonez-Llanos, J.; Sanchez-Quesada, J.L. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. *Atherosclerosis* 2004, 177, 299–305. [CrossRef]

95. Ke, L.Y.; Stancel, N.; Bair, H.; Chen, C.H. The underlying chemistry of electronegative LDL's atherogenicity. *Curr. Atheroscler. Rep.* 2014, 16, 428. [CrossRef] [PubMed]

96. Lu, J.; Yang, J.H.; Burns, A.R.; Chen, H.H.; Tang, D.; Walterscheid, J.P.; Suzuki, S.; Yang, C.Y.; Sawamura, T.; Chen, C.H. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. *Circ. Res.* 2009, 104, 619–627. [CrossRef] [PubMed]

97. Benitez, S.; Canals, F.; Benitez, S.; Colome, N.; Julve, J.; Ordonez-Llanos, J.; Sanchez-Quesada, J.L. Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages. *Cells* 2020, 9, 583. [CrossRef]
104. Sawada, N.; Obama, T.; Koba, S.; Takaki, T.; Iwamoto, S.; Aiuchi, T.; Kato, R.; Kikuchi, M.; Hamazaki, Y.; Itabe, H. Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL. *J. Lipid Res.* 2020, 61, 816–829. [CrossRef]

105. Itabe, H.; Yamamoto, H.; Imanaka, T.; Shimamura, K.; Uchiyama, H.; Kimura, J.; Sanaka, T.; Hata, Y.; Takano, T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. *J. Lipid Res.* 1996, 37, 45–53.

106. Itabe, H.; Suzuki, K.; Tsukamoto, Y.; Komatsu, R.; Ueda, M.; Mori, M.; Higashi, Y.; Takano, T. Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein. *Biochim. Biophys. Acta* 2000, 1487, 233–245. [CrossRef]

107. Tani, M.; Kawakami, A.; Mizuno, Y.; Imase, R.; Ito, Y.; Kondo, K.; Ishii, H.; Yoshida, M. Small dense LDL enhances THP-1 macrophage foam cell formation. *J. Atheroscler. Thromb.* 2011, 18, 698–704. [CrossRef]

108. Hoogeveen, R.C.; Gaubatz, J.W.; Sun, W.; Dodge, R.C.; Crosby, J.R.; Jiang, J.; Couper, D.; Virani, S.S.; Watts, G.F.; Chan, D.C. Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot? *J. Am. Coll. Cardiol.* 2020, 75, 2136–2139. [CrossRef] [PubMed]

109. Syvänné, M.; Taskinen, M.-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. *Lancet* 1997, 350, S20–S23. [CrossRef]

110. Packard, C.J.; Demant, T.; Stewart, J.P.; Bedford, D.; Caslake, M.J.; Schwertfeger, G.; Bedynek, A.; Shepherd, J.; Seidel, D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. *J. Lipid Res.* 2000, 41, 305–318. [PubMed]

111. Koba, S.; Hirano, T.; Murayama, S.; Kotani, T.; Tsunoda, F.; Iso, Y.; Ban, Y.; Kondo, T.; Suzuki, H.; Katagiri, T. Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. *Atherosclerosis* 2003, 170, 131–140. [CrossRef]

112. Koba, S.; Hirano, T.; Murayama, S.; Kotani, T.; Tsunoda, F.; Iso, Y.; Ban, Y.; Kondo, T.; Suzuki, H.; Katagiri, T. Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. *Atherosclerosis* 2003, 170, 131–140. [CrossRef]

113. Galeano, N.F.; Milne, R.; Marcel, Y.L.; Walsh, M.T.; Levy, E.; Ngu’yen, T.D.; Gleeson, A.; Arad, Y.; Witte, L.; Al-Haideri, M.; et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. *J. Biol. Chem.* 1994, 269, 511–519.

114. Galeano, N.F.; Al-Haideri, M.; Keyserman, F.; Rumsey, S.C.; Deckelbaum, R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity. *J. Lipid Res.* 1998, 39, 1263–1273.

115. Drechsler, M.; Megens, R.T.; van Zandvoort, M.; Weber, C.; Soehnlein, O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. *Circulation* 2010, 122, 1837–1845. [CrossRef] [PubMed]

116. Doring, Y.; Drechsler, M.; Soehnlein, O.; Weber, C. Neutrophils in atherosclerosis: from mice to man. *Atherosclerosis*. *Thromb. Vasc. Biol.* 2015, 35, 288–295. [CrossRef]

117. Doring, Y.; Soehnlein, O.; Weber, C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. *Circ. Res.* 2017, 120, 736–743. [CrossRef] [PubMed]

118. Kato, R.; Mori, C.; Kitazato, K.; Arata, S.; Obama, T.; Mori, M.; Takahashi, K.; Aiuchi, T.; Takano, T.; Itabe, H. Transient increase in plasma oxidized LDL during the progression of atherosclerosis in apolipoprotein E knockout mice. *Arter. Thromb. Vasc. Biol.* 2009, 29, 33–39. [CrossRef]

119. Obama, T.; Ohnata, H.; Takaki, T.; Iwamoto, S.; Sawada, N.; Aiuchi, T.; Kato, R.; Itabe, H. Cooperative action of oxidized low-density lipoproteins and neutrophils on endothelial inflammatory responses through neutrophil extracellular trap formation. *Front Immunol.* 2019, 10, 1899. [CrossRef]

120. Jaipersad, A.S.; Lip, G.Y.; Silverman, S.; Shantsila, E. The role of monocytes in angiogenesis and atherosclerosis. *J. Am. Coll. Cardiol.* 2014, 63, 1–11. [CrossRef]

121. Cao, W.; Abdelgawwad, M.S.; Li, J.; Zheng, X.L. Apolipoprotein B100/low-density lipoprotein regulates proteolysis and functions of von Willebrand factor under arterial shear. *Thromb. Haemost.* 2019, 119, 1933–1946. [CrossRef] [PubMed]

122. Awasthi, D.; Nagarkoti, S.; Kumar, A.; Dubey, M.; Singh, A.K.; Pathak, P.; Chandra, T.; Barthwal, M.K.; Dikshit, M. Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. *Free Rad. Biol. Med.* 2016, 93, 190–203. [CrossRef] [PubMed]
123. Yotsumoto, S.; Muroi, Y.; Chiba, T.; Ohmura, R.; Yoneyama, M.; Magarisawa, M.; Dodo, K.; Terayama, N.; Sodeoka, M.; Aoyagi, R.; et al. Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation. *Sci. Rep.* 2017, 7, 16026. [CrossRef]

124. Sun, L.; Ishida, T.; Yasuda, T.; Kojima, Y.; Honjo, T.; Yamamoto, Y.; Yamamoto, H.; Ishibashi, S.; Hirata, K.; Hayashi, Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. *Cardiovasc. Res.* 2009, 82, 371–381. [CrossRef]

125. Collison, K.S.; Parhar, R.S.; Saleh, S.S.; Meyer, B.F.; Kwaasi, A.A.; Hammami, M.M.; Schmidt, A.M.; Stern, D.M.; Al-Mohanna, F.A. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). *J. Leuko Biol.* 2002, 71, 433–444.

126. Corriden, R.; Hollands, A.; Olson, J.; Derieux, J.; Lopez, J.; Chang, J.T.; Gonzalez, D.J.; Nizet, V. Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide. *Nat. Commun.* 2015, 6, 8369. [CrossRef] [PubMed]

127. Meher, A.K.; Spinosa, M.; Davis, J.P.; Pope, N.; Laubach, V.E.; Su, G.; Serbulea, V.; Leitinger, N.; Ailawadi, G.; Upchurch, G.R., Jr. Novel role of IL (interleukin)-1beta in neutrophil extracellular trap formation and abdominal aortic aneurysms. *Arter. Thromb. Vasc. Biol.* 2018, 38, 843–853. [CrossRef]

128. Hollands, A.; Corriden, R.; Gysler, G.; Daheb, S.; Olson, J.; Raza Ali, S.; Kunkel, M.T.; Lin, A.E.; Forli, S.; Newton, A.C.; et al. Natural product anacardic acid from cashew nut shells stimulates neutrophil extracellular trap production and bactericidal activity. *BioChem* 2016, 291, 13964–13973. [CrossRef]

129. Zhao, X.; Yang, L.; Chang, N.; Hou, L.; Zhou, X.; Yang, L.; Li, L. Neutrophils undergo switch of apoptosis to NETosis during murine fatty liver injury via S1P receptor 2 signaling. *Cell Death Dis.* 2020, 11, 379. [CrossRef]

130. Kurano, M.; Yatomi, Y. Sphingosine 1-Phosphate and Atherosclerosis. *Prog. Lipid Res.* 2006, 45, 426–436. [CrossRef] [PubMed]

131. O’Neil, L.J.; Kaplan, M.J.; Carmona-Rivera, C. The role of neutrophils and neutrophil extracellular traps in vascular damage in systemic lupus erythematosus. *J. Clin. Med.* 2019, 8, 1325. [CrossRef]

132. Deniset, J.F.; Kubes, P. Neutrophil heterogeneity: Bona fide subsets or polarization states? *J. Atheroscler. Thromb.* 2018, 25, 16–26. [CrossRef] [PubMed]

133. Carmona-Rivera, C.; Kaplan, M.J. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. *Semin. Immunopathol.* 2013, 35, 455–463. [CrossRef] [PubMed]

134. Villanueva, E.; Yalavarthi, S.; Berthier, C.C.; Hodgjin, J.B.; Khandpur, R.; Lin, A.M.; Rubin, C.J.; Zhao, W.; Olsen, S.H.; Klinker, M.; et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. *J. Immunol.* 2011, 187, 538–552. [CrossRef]

135. Lopez, D.; Garcia-Valladares, I.; Palafox-Sanchez, C.A.; De La Torre, I.G.; Kobayashi, K.; Matsuura, E.; Lopez, L.R. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. *Am. J. Clin. Pathol.* 2004, 121, 426–436. [CrossRef] [PubMed]

136. Matsuura, E.; Kobayashi, K.; Tabuchi, M.; Lopez, L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. *Prog. Lipid Res.* 2008, 47, 558–566. [CrossRef]

137. Zha, C.; Zhang, W.; Gao, F.; Xu, J.; Jia, R.; Cai, J.; Liu, Y. Anti-beta2GPI/beta2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. *Neuropharmacology* 2018, 138, 140–150. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).